openPR Logo
Press release

Breast milk as a weapon against cancer

04-10-2017 01:51 PM CET | Health & Medicine

Press release from: FWF

In an FWF-funded project, scientists at the University of Graz modified and reinforced a host defence peptide from breast milk so as to enable it to specifically detect cancer cells. The active substance can then induce cell death. Research continues on this new therapeutic approach to types of cancer with limited treatability.

Many types of cancer respond well to treatment if detected early and treated with effective chemotherapy. But types that are poorly treatable include skin cancer and brain cancer (glioblastoma) as well as metastases, i.e. tumour cells spreading to remote parts of the body via the bloodstream. But even the most malignant cancer cell has a weak spot, an Achilles heel. Unlike healthy cells, the membrane enveloping cancer cells carries on its outer side negatively charged molecules, the lipid phosphatidylserine (PS). This means that PS can serve as a marker for cancer. With the support of the Austrian Science Fund FWF, a team from the Department of Molecular Biosciences at the University of Graz has developed a new weapon that selectively targets this Achilles heel.

Peptide arrow carved from breast milk

In a preceding FWF project, the team of principal investigator Dagmar Zweytick had already ascertained that the PS cancer marker was an appropriate target for anti-tumour medication, since it was detectable on membranes of various types of cancer and even metastases. In the present follow-up project, the team has now managed to hone a human defence peptide into an arrow that targets cancer cells. A modified and strengthened active part of the peptide lactoferricin, which is found in a precursor in breast milk, identifies various types of cancer cells, including melanoma and glioblastoma. The positively charged peptide arrows selectively locate the negatively charged PS-exposed on the surface of cancer cells, dock on to them and within a few hours induce cell death (a command that is otherwise blocked in cancer cells). The peptide variants do not, however, interact with healthy cells of the body.

Killing cancer without harming healthy cells

"The biggest challenge in the design process was to find the right balance of toxicity and specificity. If the peptides are made too active, they will also attack healthy cells. In control tests we always made sure that the peptides locate only cancer cells and leave normal cells untouched", explain principal investigator Dagmar Zweytick and postdoc researcher Sabrina Riedl. The biophysicist has been working on lactoferricin since 2002. A precursor of the small protein molecule is present in breast milk, a substance that not only nourishes a new-born child but also helps it build a strong antimicrobial defence system. As part of the innate immune system, lactoferricin is the body’s first defence reaction against negatively charged non-host cells such as bacteria and fungi, but also against mutated body cells, such as cancer cells. Before the defence peptide can be used as an anti-tumour weapon, it has to be rebuilt in a directed manner to be improved in its activity. Between July 2012 and June 2016, a team of five members worked on the ideal arrangement of the chemical building blocks (amino acids) of the active peptide constituent which is shaped like a hairpin. The team started the design process by simulating variants of promising activity levels in a computer model. About fifteen variants of the substance were synthesised on the basis of these designs and then tested on membrane models and "in vitro" on cancer cell lines.

Tumour regression in the mouse model

In collaboration with Beate Rinner from the Medical University of Graz, the two most auspicious variants were tested "in vivo". The researchers compared peptide-treated and untreated mouse xenotransplants (mice growing human cancer cells). In the cancer mice treated with peptide, the researchers observed a strong or even complete regression of the tumours, achieving an average of 85% regression in the case of melanoma and up to 50% in the case of glioblastoma when compared with untreated cancer mice. A third control group of healthy mice remained unharmed when treated with the agent. The modified variants showed an effectiveness about ten times greater than the original breast milk peptide.

The active peptide variants with an anti-tumour effect have already been patented in the EU and the USA (respectively are patent pending). The team around Dagmar Zweytick is now collaborating with a pharmaceutical company in the context of a project financed by the Austrian Research Promotion Agency FFG in preparation of pre-clinical studies. The new anti-tumour agent should preferably be administered intravenously so as to reach metastases as well. Issues being currently tested include how stable the peptide arrow is in the blood system, whether it can cross the blood-brain barrier and how the arrowhead can be sharpened further.

Personal details
Dagmar Zweytick (https://molekularbiologie.uni-graz.at/en/research/areas-of-research/biophysics/), assistant professor at the Institute of Molecular Biosciences (https://molekularbiologie.uni-graz.at/en/) at the University of Graz, heads the anti-tumour-peptide research group in the biophysics division. She studied technical chemistry and acquired her PhD in biochemistry and food chemistry at the University of Technology in Graz. During ten years as a senior scientist at the Austrian Academy of Sciences she already focused on defence peptides.

Publications

Riedl S., Leber R., Rinner B., Schaider H., Lohner K. and Zweytick D.: "Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserine", in Biochim. Biophys. Acta 1848 (11) (2015) 2918-2931. http://doi.org/f3sxf9

Riedl S., Rinner B., Schaider H., Lohner K. and Zweytick D.: "Killing of melanoma cells and their metastases by human lactoferricin derivatives requires interaction with the cancer marker phosphatidylserine", in Biometals 27 (5) (2014) 981-997. http://doi.org/f3sqdp

Riedl S., Rinner B., Asslaber M., Schaider H., Walzer S., Novak A., Lohner K. and Zweytick D.: "In search of a novel target – Phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy", in Biochim. Biophys. Acta 1808 (2011) 2638-2645. http://doi.org/d5zsdk

Image and text will be available as of Monday, 10th April 2017, from 9.00 am CET at: http://scilog.fwf.ac.at/en

Scientific Contact
Ass.-Prof. Dr. DI Dagmar Zweytick
University of Graz
Institute of Molecular Biosciences
Biophysics Division
Humboldtstraße 50/III
8010 Graz, Austria
T +43 / 316 / 380 4988
E dagmar.zweytick@uni-graz.at
W https://molekularbiologie.uni-graz.at/en/

Austrian Science Fund FWF
Ingrid Ladner
Haus der Forschung
Sensengasse 1
1090 Vienna, Austria
T +43 / 1 / 505 67 40 - 8117
E ingrid.ladner@fwf.ac.at
W http://scilog.fwf.ac.at/en/
W http://www.fwf.ac.at/en

Distribution
PR&D – Public Relations for Research and Education
Mariannengasse 8
1090 Vienna, Austria
T +43 / 1 / 505 70 44
E contact@prd.at
W http://www.prd.at/en

The purpose of the FWF is to support the ongoing development of Austrian science and basic research at a high international level. In this way, the FWF makes a significant contribution to cultural development, to the advancement of our knowledge-based society, and thus to the creation of value and wealth in Austria.

Austrian Science Fund FWF
Ingrid Ladner
Haus der Forschung
Sensengasse 1
1090 Vienna, Austria
T +43 / 1 / 505 67 40 - 8117
E ingrid.ladner@fwf.ac.at
W scilog.fwf.ac.at/en/
W fwf.ac.at/en

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Breast milk as a weapon against cancer here

News-ID: 496781 • Views: 645

More Releases from FWF

12-12-2005 | Health & Medicine
FWF
Sparking Hearts: SPARC Promotes Heart Muscle Formation from Stem Cells
The protein SPARC plays a key role in the development of heart muscle in the embryo. An Austrian Science Fund FWF project has discovered this previously unknown role of SPARC. The protein has a significant effect on the activity of the genes that are responsible for the emergence of heart cells from initially undifferentiated embryonic stem cells. The results of this project, carried out at the Medical University of Vienna,
11-02-2005 | Science & Education
FWF
Brown Bears: The Guile and Wile of Reproduction
Female brown bears are driven to having many partners - not because of lust but as part of a sophisticated strategy for protecting future offspring. This surprising discovery is the result of a large-scale project by the Austrian Science Fund FWF in which the bear population in Scandinavia was closely observed in the wild. The data, that goes back for over 20 years, is published today and is contributing to

More Releases for Austria

Agrochemicals Market in Austria
ReportsWorldwide has announced the addition of a new report title Austria: Agrochemicals: Market Intelligence (2016-2021) to its growing collection of premium market research reports. The report “Austria: Agrochemicals: Market Intelligence (2016-2021)” provides market intelligence on the different market segments, based on type, active ingredient, formulation, crop, and pest. Market size and forecast (2016-2021) has been provided in terms of both, value (000 USD) and volume (000 KG) in the report. A
Nazi psychology in Austria
The history of academic psychology after the "Anschluss", the annexation of Austria by Germany in 1938, and its role as a discipline used in National Socialist policies is being examined systematically for the first time in a research project supported by the Austrian Science Fund FWF. "It is a sad fact”, says psychologist Gerhard Benetka from the Sigmund Freud University Vienna "that applied psychology flourished during the National Socialist era
Creative Austria meets creative Russia
Euroforum: communicatin ready for the next lap Vienna. On 22nd of October 2009 the advertising association Vienna invites again to the annual Euroforum: communication event, platform for European communication, guaranteeing an interesting mix of “connecting businesses and communications”. The Event takes place in Studio 44, Vienna. Focus point Russia (Moscow, St. Petersburg and Sotschi) The main goal of the Euroforum is to promote and establish business relations and synergies between
New partner in Germany and Austria
Newly-appointed Noliac Group partner Mr. Stamm will react to increasing mid-European demand by being close to customers and ensure proficient piezo support at hand. Mr. Ralf Stamm is former Key Account Manager of Physik Instrumente (PI) and has the expertise to provide Noliac Group's customers with a first class support within the field of piezoceramics. 17 years of piezo experience As of August 4th 2009, Mr. Ralf Stamm became Noliac Group’s
Winning Business in Germany, Austria & Switzerland Workshop
Wednesday, 29th April 2009 8.30am –12.30pm Enterprise Ireland, The Plaza, East Point Business Park, Dublin 3 A round table session on the unique business cultures, opportunities and strategies associated with and required in Europe’s German-speaking markets. This workshop, facilitated by Enterprise Ireland with support from the Ariston Group, a German based consultancy company, and Trinity College, Department of Germanic Studies, has been designed to bring Irish companies quickly up to speed with the
Archaeological Sensation in Austria
Scientists from the University of Vienna unearth the earliest evidence of Jewish inhabitants in Austria Archaeologists from the Institute of Prehistory and Early History of the University of Vienna have found an amulet inscribed with a Jewish prayer in a Roman child's grave dating back to the 3rd century CE at a burial ground in the Austrian town of Halbturn. The 2.2-centimeter-long gold scroll represents the earliest sign of